|
|
 |
|
|
|
|
12. R. Comis. Oral etoposide: a developing role. Eur. J. Cancer 27(Suppl. 2): 5348, 1991. |
|
|
|
|
|
|
|
|
13. D. Bissett, A. Steanoians, J. Cassidy, M. A. Graham, G. A. Chadwick, P. Wilson, V. Auzannet, N. Le Bail, S. B. Kaye, and D. J. Kerr. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24 hour infusion. Cancer Research 53: 523527, 1993. |
|
|
|
|
|
|
|
|
14. J. Cassidy. Chemotherapy administration: doses, infusions and choice of schedule. Annals of Oncology 5(Suppl. 4): 2530, 1994. |
|
|
|
|
|
|
|
|
15. J. M. Collins, D. S. Zaharko, R. Dedrick, et al. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 7380, 1986. |
|
|
|
|
|
|
|
|
16. EORTC pharmacokinetics and metabolism group. Pharmacokinetically guided dose escalation in phase I clinical trials. Eur. J. Can. Clin. Oncol. 23: 10831087, 1987. |
|
|
|
|
|
|
|
|
17. M. A. Graham and P. Workman. The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: Critical evaluation and recommendations for future studies. Annals of Oncology 3: 338349, 1992. |
|
|
|
|
|
|
|
|
18. J. O'Quigley, M. Pepe, and L. Fisher. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46: 3348, 1990. |
|
|
|
|
|
|
|
|
19. D. Faries. The modified continual reassessment method for Phase I cancer clinical trials. Proc. of Amer. Stat. Assoc. 1991. |
|
|
|
|
|
|
|
|
20. W. E. Evans, J. H. Rodman, M. V. Relling, W. R. Crom, G. K. Rivera, C. B. Pratt, and W. M. Crist. Concept of maximal tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Medical and Paediatric Oncology 19: 153159, 1991. |
|
|
|
|
|
|
|
|
21. J. Cassidy. Biological end points in early clinical trials of antineoplastic drugs. CRC Beatson Laboratories Scientific Report 2123, 1993. |
|
|
|
|
|
|
|
|
22. S. K. Carter. Study design principles of the clinical evaluation of new drugs as developed by the chemotherapy program of the National Cancer Institute. In The Design of Clinical Trials in Cancer Therapy. M. Staquet, Ed. Brussels, Editions Scientifique Europeennes, 1973, p. 242247. |
|
|
|
|
|
|
|
|
23. G. Schwartsmann, J. Wanders, I. J. Koier, et al. EORTC New Drug Development Office co-ordinating and monitoring programme for phase I and II trials with new anticancer agents. Eur. J. Cancer 27: 11621168, 1991. |
|
|
|
|
|
|
|
|
24. F. M. Muggia, M. Rozencweig, M. J. Stawuet, and W. P. McGuire. In Methodology of Phase II Trials in Cancer. S. K. Carter and Y. Sakurai, Eds. New anticancer agents. Springer, New York, 1980. |
|
|
|
|
|
|
|
|
25. S. B. Kaye, P. Workman, M. A. Graham, J. Cassidy, and D. Jodrell. Pharmacokinetics and early clinical studies of selected new drugs. Cancer Surveys 17: 371395, 1993. |
|
|
|
|
|
|
|
|
26. J. Cassidy and S. B. Kaye. New drugs in clinical development in Europe. Haematology/Oncology Clinics of North America 8: 289303, 1994. |
|
|
|
|
|
|
|
|
27. J. Carmichael. Cancer chemotherapy: identifying novel anticancer drugs. Br. Med. J. 308: 12881290, 1994. |
|
|
|
|
|